Compare
NRX Pharmaceuticals, Inc. vs Cannapharmarx, Inc. vs IGC Pharma, Inc. vs Longeveron Inc.
| Latest fiscal year | NRX Pharmaceuticals, Inc. NRXP | Cannapharmarx, Inc. CPMD | IGC Pharma, Inc. IGCLast annual report: year ended 2025-03-31 | Longeveron Inc. LGVN |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-03-31 | 2025-12-31 |
| Revenue | $1.45M | $1.36M | $1.27M | $1.20M |
| Revenue growth (YoY) | n/a | +66.1% | -5.5% | -49.9% |
| Gross margin | 65.1% (computed) | -153.1% | 48.7% | 67.0% |
| Operating margin | n/m | -245.8% | -585.8% | n/m |
| Net margin | n/m | -817.2% | -560.3% | n/m |
| Net income | -$28.62M | -$11.13M | -$7.12M | -$22.70M |
| EPS (Diluted) | n/a | -$0.02 | -$0.09 | -$1.29 |
| Operating cash flow | -$14.11M | -$789.1K | -$4.79M | -$18.64M |
| Free cash flow | n/a | -$794.6K | -$4.91M | -$18.89M |
| Cash & equivalents | $7.80M | $1.8K | $405.0K | $4.66M |
| Total assets | $12.96M | $7.02M | $8.75M | $10.26M |
| Total liabilities | $28.89M | $37.17M | $2.42M | $4.59M |
| Shareholders' equity | -$15.94M | -$30.15M | $6.33M | $5.67M |
| Return on year-end equity | n/a | n/a | -112.5% | -400.1% |
| Shares outstanding | 31.73M | 662.50M | 80.88M | n/a |
Revenue, most recent five fiscal years
| Fiscal year | NRX Pharmaceuticals, Inc. | Cannapharmarx, Inc. | IGC Pharma, Inc. | Longeveron Inc. |
|---|---|---|---|---|
| Latest | $1.45M Ended 2025-12-31 | $1.36M Ended 2025-12-31 | $1.27M Ended 2025-03-31 | $1.20M Ended 2025-12-31 |
| 1 year earlier | $0 Ended 2024-12-31 | $820.1K Ended 2024-12-31 | $1.34M Ended 2024-03-31 | $2.39M Ended 2024-12-31 |
| 2 years earlier | $0 Ended 2023-12-31 | $0 Ended 2023-12-31 | $911.0K Ended 2023-03-31 | $709.0K Ended 2023-12-31 |
| 3 years earlier | n/a | $0 Ended 2022-12-31 | $397.0K Ended 2022-03-31 | $1.22M Ended 2022-12-31 |
| 4 years earlier | n/a | $0 Ended 2021-12-31 | $898.0K Ended 2021-03-31 | $1.31M Ended 2021-12-31 |